1 / 6

Reports and Intelligence: Non-Small Cell Lung Cancer Market

GBI Research, a leading business intelligence provider, has released its latest research report, “Non-Small Cell Lung Cancer Market to 2020 - New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market”. The value of the Non-Small Cell Lung Cancer (NSCLC) market is expected to increase significantly over the forecast period across the leading eight developed nations, from $5.1 billion in 2013 to $7.9 billion in 2020. This equates to a Compound Annual Growth Rate (CAGR) of 6.6%. Detailed report at: http://www.reportsandintelligence.com/global-3d-printing-materials-2014-2018-market

RyanAddison111
Download Presentation

Reports and Intelligence: Non-Small Cell Lung Cancer Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Non-Small Cell Lung Cancer Market to 2020 New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market Published on: July 2014 No. of Pages: 143 Reports and Intelligence

  2. Description GBI Research, a leading business intelligence provider, has released its latest research report, “Non-Small Cell Lung Cancer Market to 2020 - New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market”. The value of the Non-Small Cell Lung Cancer (NSCLC) market is expected to increase significantly over the forecast period across the leading eight developed nations, from $5.1 billion in 2013 to $7.9 billion in 2020. This equates to a Compound Annual Growth Rate (CAGR) of 6.6%. Growth will be driven by novel therapies entering the squamous cell carcinoma market segment, which is currently lacking effective treatment, unlike the non-squamous market segment. The report focuses on the increasing differentiation between the three main NSCLC subtypes: squamous cell, adenocarcinoma, and large cell carcinoma. Common genetic and molecular aberrations within these histologies are being extensively researched and targeted by novel therapeutics and so the treatment algorithm between histological subtypes is forecast to become more differentiated over the forecast period. Most notably, patients with squamous cell carcinoma are set to benefit from crucial first- and second-line therapies in the form of Yervoy (ipilimumab) and nivolumab, having relied on generic chemotherapy for the past decade. 

  3. Table Of Content Introduction  Marketed Products NSCLC Pipeline Market Forecast Strategic Consolidations Appendix  Get full access to TOC at: http://www.reportsandintelligence.com/non-small-cell-lung-cancer-to-2020-new-therapies-to-enhance-treatment-segmentation-and-drive-growth-in-an-increasingly-competitive-market/table-of-contents

  4. Scope • A disease introduction, which defines the disease and looks at symptoms, diagnosis and treatment • Analysis of the NSCLC marketed landscape, including a comparison of the efficacy and safety of the most prominent brands, as well as the unmet needs of NSCLC treatment • Detailed analysis of the NSCLC pipeline, covering among other parameters, drug distribution by Phase, molecule type and mechanism of action. The NSCLC clinical trial landscape is analyzed with particular emphasis on failure rates across different trial Phases, as well as the trends in clinical trial size, duration and primary endpoint. This section also includes profiles and single product forecasts for the most promising pipeline drugs. • An epidemiological forecast of the major NSCLC markets, in which projected values include total and treated populations • An overview of the drivers of and barriers to the NSCLC market

  5. Reasons To Buy • Understand the NSCLC pipeline and the clinical needs that it is addressing, particularly the ways in which histology affects treatment options and where in the treatment algorithm new products will be positioned, as well as where unmet needs remain • Develop their knowledge of key products that may enter the market before 2020. Detailed profiles of these products are provided, with a focus on their clinical trial performance, as well as how they can be incorporated into the NSCLC treatment plan and what competition they face. • Assess the risk associated with NSCLC product development profiled by molecule type and mechanism of action and compared with both industry and therapy-area averages. In addition, data analyses offer a more detailed understanding of the trends in both trial size and duration for specific mechanisms of action or molecule types. The primary endpoint analysis infers trends in trial design within the therapy area, as well as the endpoints that are the best indicators of success.

  6. Get access to detailed information at: http://www.reportsandintelligence.com/non-small-cell-lung-cancer-to-2020-new-therapies-to-enhance-treatment-segmentation-and-drive-growth-in-an-increasingly-competitive-market Request for Discount at: http://www.reportsandintelligence.com/purchase-enquiry/132454

More Related